{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:15:43Z","timestamp":1776309343408,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"22","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Cystatin\u2010C (Cys\u2010C) is a predictor of several malignancies. However, whether Cys\u2010C levels predict prognosis in patients with papillary renal cell carcinoma (PRCC) remains uncertain. The aim of this study was to assess the correlation between Cys\u2010C and clinical outcomes in patients with PRCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The medical records of 137 patients with PRCC who underwent surgery at our institution from January 2008 to December 2020 were retrospectively analyzed. Data were divided into two subgroups based on cutoff values and the relationship between the Cys\u2010C group and their clinical outcomes was assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>By the last follow\u2010up, 62 patients had died of various causes, 53 of whom died from PRCC. Sixty patients suffered recurrence or metastasis during follow\u2010up. Based on the cutoff value, the patients were divided into two groups: low Cys\u2010C group (Cys\u2010C &lt;\u20091.25\u2009mg\/L, <jats:italic>n<\/jats:italic>\u00a0=\u00a092) and high Cys\u2010C group (Cys\u2010C\u2009\u2265\u20091.25\u2009mg\/L, <jats:italic>n<\/jats:italic>\u00a0=\u00a045). Pathological classification and serum Cys\u2010C levels were shown to be independent prognostic factors affecting clinical outcomes, according to multivariate Cox regression analysis (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). After adjusting the Cox proportional hazards model, the risk of death was elevated in the high Cys\u2010C group. The results of the area under the curve for time\u2010dependent receiver operating characteristics analysis indicated that Cys\u2010C is a stable and reliable prognostic biomarker for predicting survival in patients with PRCC. Forest plots, constructed to better reflect the comparison of hazard ratios between the two groups, confirmed that Cys\u2010C levels were significantly associated with worsening overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study is the first to examine the relationship between preoperative serum Cys\u2010C levels and prognostic overall survival in patients with PRCC. Cys\u2010C may be a useful biomarker for preoperative screening of high\u2010risk patients who may require adjuvant therapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4731","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:49:12Z","timestamp":1649152152000},"page":"4112-4121","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between preoperative serum <scp>Cystatin\u2010C<\/scp> levels and postsurgical oncological prognosis in patients with <scp>PRCC<\/scp>: A retrospective cohort study"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7235-4332","authenticated-orcid":false,"given":"Shiyang","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Urology Shengjing Hospital of China Medical University  Shenyang PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology Shengjing Hospital of China Medical University  Shenyang PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000220"},{"issue":"6","key":"e_1_2_11_3_1","first-page":"537","article-title":"Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors","volume":"10","author":"Delahunt B","year":"1997","journal-title":"Mod Pathol"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2001.24984"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00506-2"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010115)91:2<354::AID-CNCR1009>3.0.CO;2-9"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.12.035"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-2011-0176"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.31173"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.40961"},{"issue":"6","key":"e_1_2_11_11_1","first-page":"3463","article-title":"Preoperative Leucocytosis, thrombocytosis and anemia as potential prognostic factors in non\u2010metastatic renal cell carcinoma","volume":"35","author":"Hutterer GC","year":"2015","journal-title":"Anticancer Res"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22688"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68975-3"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.07.004"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1829481"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.000638"},{"issue":"2","key":"e_1_2_11_17_1","first-page":"505","article-title":"Cysteine proteinase inhibitors stefin a, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis","volume":"6","author":"Kos J","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178823"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.08.083"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2016(06)09"},{"key":"e_1_2_11_23_1","first-page":"2617439","article-title":"Serum Cystatin C level is not a promising biomarker for predicting Clinicopathological characteristics of bladder Urothelial tumors","volume":"2018","author":"Wang H","year":"2018","journal-title":"Biomed Res Int"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2018.04.013"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3084-9"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbacli.2017.03.001"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2016.1222416"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20271"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2005.04.001"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2018.01.006"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.183.2.3"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.1999.00964.x"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.6.4020"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-02957-w"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0080-9"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000091"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-014-1311-8"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.03.003"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4731","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4731","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T05:51:33Z","timestamp":1692683493000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":37,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/cam4.4731"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4731","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"2021-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}